论文部分内容阅读
目的:通过对南京地区34家医院2012-2014年溶栓抗凝药物利用情况的分析,评价南京地区2012-2014年溶栓抗凝药物的使用合理性,评估现状与趋势。方法:采用金额和用药频度分析及排序法进行药物利用分析。结果:3年南京地区溶栓抗凝药物DDDs和总用药金额呈逐年增加趋势,但增长率为下降趋势。从亚类来看,纤溶酶原非特异性药物销售金额逐年下降,所占总额比重低于特异性药物,但从DDDs来看纤溶酶原特异性药物却低于非特异性药物。抗凝药物中肠外抗凝药物销售金额增加趋于平稳,而口服抗凝药物增长迅速,尤其是新型口服抗凝药物,DDDs排名仍是华法林为首位。结论:南京34家医院溶栓抗凝药物临床使用基本能遵循指南要求,但应继续加强医院溶栓抗凝类药物的临床合理使用监测,尽量做到个体化给药,防止药物不良反应的发生,真正做到合理、安全、经济、有效。
Objective: To evaluate the use of thrombolysis anticoagulants in Nanjing in 2012-2014 by analyzing the utilization of thrombolytic anticoagulants in 34 hospitals in Nanjing from 2012 to 2014, and to evaluate the status quo and trends. Methods: The use of the amount and frequency of drug analysis and sequencing analysis of drug use. Results: The DDDs and the total amount of drugs for thrombolytic anticoagulation in Nanjing area showed an increasing trend year by year, but the growth rate showed a downward trend. From a subclass point of view, the amount of non-specific plasminogen sales decreased year by year, the proportion of the total proportion of lower than the specific drugs, but DDDs plasminogen-specific drugs are lower than non-specific drugs. Sales of anticoagulants in anticoagulants increased steadily while sales of oral anticoagulants increased rapidly. Especially for new oral anticoagulants, DDDs ranked the top among warfarin. Conclusion: The clinical use of thrombolytic anticoagulants in 34 hospitals in Nanjing basically can follow the guidelines, but should continue to strengthen the clinical rational use of thrombolytic anticoagulants in hospitals, try to individualized administration and prevent the occurrence of adverse drug reactions , Truly reasonable, safe, economical and effective.